Residency · Residency · Interventional Radiology
Lung Tumor Ablation: Technique and Outcomes
Overview
Percutaneous image-guided ablation of lung tumors is an established treatment for medically inoperable early-stage NSCLC and oligometastatic pulmonary disease. Modalities include radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation. CT guidance is standard; general anesthesia or moderate sedation depending on institution. Positioned as an alternative to stereotactic body radiation therapy (SBRT) and surgical resection in non-surgical candidates.
Indications
Primary Lung Cancer
Stage IA NSCLC (T1a–T1c, ≤3 cm) in patients who are medically inoperable. Medically inoperable defined by: poor pulmonary reserve (FEV1 <40% predicted), severe cardiovascular disease, or patient refusal of surgery. Best outcomes for peripheral tumors ≤2 cm.
Metastatic Disease
Oligometastatic pulmonary disease (typically ≤3–5 metastases). Controlled primary malignancy with limited or no extrapulmonary disease. Common primaries: colorectal carcinoma, renal cell carcinoma, sarcoma, hepatocellular carcinoma. Used in "test of time" approach — observe for new metastases before committing to ablation.
Relative Contraindications
Tumors >3 cm (higher local recurrence rates). Central tumors (near hilum, major vessels, or airways). Proximity to mediastinal structures, esophagus, or heart. Severe uncorrectable coagulopathy. Contralateral pneumonectomy (pneumothorax would be catastrophic).
Ablation Modalities
| Feature | RFA | MWA | Cryoablation |
|---|---|---|---|
| Current use | Declining | Most common for lung | Alternative |
| Ablation time | 12-20 min | 3-10 min | 20-30 min (2 cycles) |
| Visualization | GGO on CT | GGO on CT | Ice ball (excellent) |
| Pain | Moderate | Moderate | Less (sedation possible) |
| Impedance limitation | Yes (aerated lung) | No | N/A |
| Hemorrhage risk | Low (cauterizes) | Low (cauterizes) | Higher (no coagulation) |
| Best application | Longest published data | Preferred for most lung tumors | Near chest wall, pain-sensitive |
Radiofrequency Ablation (RFA)
First modality widely used for lung ablation. Aerated lung provides natural insulation, theoretically enhancing ablation zone. However, impedance of aerated lung can also limit current flow. Ground-glass opacity (GGO) surrounding the ablation zone is expected post-procedure. Most published long-term data available for RFA.
Microwave Ablation (MWA)
Currently the most commonly used modality for lung ablation. Faster ablation times, larger ablation zones, and less susceptibility to heat-sink effect. Not limited by tissue impedance (advantage in aerated lung). Can achieve more predictable spherical ablation zones. Growing evidence base with comparable or superior outcomes to RFA.
Cryoablation
Ice ball visible on CT for real-time monitoring. Less painful than heat-based modalities (can be performed under moderate sedation more readily). Advantageous near chest wall (less post-procedural pain). Risk of delayed hemorrhage (cryoablation does not cauterize vessels like heat-based modalities). Multiple probes often required for adequate coverage.
<image>CT-guided microwave ablation of a peripheral right lower lobe NSCLC showing antenna placement and surrounding ground-glass opacity during the ablation</image>
Procedural Technique
Pre-Procedural Planning
Review CT (preferably with contrast) for tumor size, location, and relationship to fissures, vessels, and airways. PFTs to assess baseline pulmonary reserve and predict tolerance for potential pneumothorax. PET-CT if available for metabolic assessment and staging confirmation. Plan patient positioning for shortest, safest access route avoiding fissures, bullae, and major vessels. Biopsy can be performed same-session if tissue diagnosis not yet confirmed.
CT-Guided Approach
Patient positioned prone, supine, or lateral decubitus depending on tumor location. Intermittent CT guidance or CT fluoroscopy for real-time needle advancement. Single-lung ventilation or bronchial blocker may improve targeting (reduces respiratory motion). Ipsilateral arm positioning to open intercostal spaces.
Ablation Execution
Place probe with tip at deep margin of tumor. Target ablation zone should encompass tumor plus ≥5 mm circumferential margin. For RFA: monitor impedance; for MWA: timed ablation per manufacturer protocol. For cryoablation: double freeze-thaw cycle, monitoring ice ball on CT. Post-ablation CT to assess for pneumothorax and ablation zone. Track ablation on withdrawal for heat-based modalities.
Pneumothorax Management
Pneumothorax occurs in 15–50% of lung ablations. Most are small and asymptomatic — observe with serial imaging. Chest tube or aspiration required in ~5–15% of cases. Risk factors: crossing fissures, emphysematous lung, central location, multiple probe passes. Blood patch technique (autologous blood injected through access tract) may reduce pneumothorax risk.
<image>Post-ablation CT showing expected ground-glass opacity ablation zone surrounding the treated tumor with a small ipsilateral pneumothorax</image>
Outcomes
Primary NSCLC
Local tumor progression: 10–30% depending on tumor size and modality. 3-year overall survival: 50–70% (reflects comorbid population). 5-year cancer-specific survival: 50–80% for stage IA. Tumors ≤2 cm have significantly better local control than 2–3 cm tumors. Complete ablation (no residual enhancement) on first follow-up is a strong predictor of durable control.
Comparison with SBRT
No completed randomized controlled trials directly comparing ablation with SBRT for early-stage NSCLC. SBRT has more robust prospective evidence (RTOG 0236, CHISEL). Retrospective comparisons suggest similar local control for tumors ≤2 cm. Ablation advantages: repeatable, preserves parenchyma, immediate tissue destruction. SBRT advantages: non-invasive, no pneumothorax risk, treats central tumors more safely. Ongoing trials (LUMIRA, others) aiming to provide direct comparison data.
Metastatic Disease
Local control: 70–90% for colorectal metastases ≤3 cm. Ablation combined with systemic therapy in oligometastatic paradigm. Repeat ablation feasible for new or recurrent metastases.
Follow-Up Imaging
CT at 1 month, then every 3 months for 2 years, then every 6 months. Expected evolution: GGO → consolidation → cavitation (sometimes) → scar/fibrosis with gradual involution. PET-CT useful at 3–6 months; persistent FDG avidity beyond 6 months suggests residual/recurrent disease. Any enlarging nodular enhancement at ablation margin is suspicious for local progression. Benign peri-ablation enhancement (rim enhancement) is common and should not be confused with recurrence.
<image>Serial follow-up CT images at 1, 6, and 12 months post-microwave ablation showing expected evolution from ground-glass opacity to consolidation to stable fibrotic scar</image>
Complications
Common
Pneumothorax (15–50%, chest tube in 5–15%). Pleural effusion (small, usually self-limited). Post-procedural pain. Mild hemoptysis.
Uncommon / Serious
Hemothorax (rare, more common with cryoablation). Bronchopleural fistula. Pulmonary abscess / cavitary infection. Air embolism (rare but potentially fatal — keep needle hub covered, avoid upright positioning with open probe). Skin burn at ground pad site (RFA). Nerve injury (phrenic, intercostal, brachial plexus depending on tumor location).
Clinical Pearls
Tumors ≤2 cm in a peripheral location are the "sweet spot" for lung ablation — local control approaches surgical outcomes. Always assess for emphysema along the planned trajectory; crossing bullae dramatically increases pneumothorax risk. MWA has largely replaced RFA as the dominant modality due to faster ablation and more predictable zones. Positioning the patient with the ablated lung dependent after the procedure can reduce pneumothorax progression. For tumors near the chest wall, cryoablation may be preferred to reduce post-procedural pain. Air embolism is the most feared complication — maintain probe seal, avoid Valsalva, and position patient appropriately. A "ground-glass halo" immediately post-ablation that is at least 5 mm larger than the tumor in all dimensions suggests adequate margin. Unlike SBRT, ablation can be repeated multiple times in the same lung without cumulative radiation concerns.
References
- Dupuy DE, et al. Radiofrequency Ablation of Stage IA Non-Small Cell Lung Cancer (ACOSOG Z4033). Cancer. 2015;121(19):3491-3498.
- de Baere T, et al. Lung Ablation: Best Practice/Research Management. Clin Radiol. 2022;77(8):579-588.
- Palussiere J, et al. Lung Tumors Treated with Percutaneous Microwave Ablation: Long-Term Results. Radiology. 2022;305(3):700-707.
- Ridge CA, et al. Percutaneous Ablation of Pulmonary Malignancies. RadioGraphics. 2023;43(1):e220065.
- Bi N, et al. SBRT vs. Thermal Ablation for Early-Stage NSCLC: Systematic Review and Meta-Analysis. J Thorac Oncol. 2023;18(5):588-598.
- Hiraki T, et al. Pneumothorax Following Lung Ablation: Incidence and Risk Factors. Radiology. 2013;267(3):940-947.
